Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
Parental prostacyclin is the only therapy with a proven survival benefit in pulmonary arterial hypertension (PAH). However, some patients are unable to tolerate continuous prostacyclin infusion because of central line infection, side effects, or sociocultural factors. Selexipag is a recently approve...
Main Authors: | Nathan Holthaus, Kurt W. Prins, Lauren Rose, Sasha Prisco, Marc Pritzker, Thenappan Thenappan |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-08-01
|
Series: | Pulmonary Circulation |
Online Access: | https://doi.org/10.1177/2045894019862167 |
Similar Items
-
Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
by: Nael Aldweib, et al.
Published: (2021-10-01) -
Selexipag in the management of pulmonary arterial hypertension: an update
by: Coghlan JG, et al.
Published: (2019-08-01) -
Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
by: Abraham Rothman, et al.
Published: (2020-02-01) -
Real-life data on Selexipag for the treatment of pulmonary hypertension
by: Michaela Barnikel, et al.
Published: (2019-02-01) -
Excess Protein O-GlcNAcylation Links Metabolic Derangements to Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
by: Sasha Z. Prisco, et al.
Published: (2020-10-01)